Organic Chemical – Page 33

BridgeBio Pharma Reports Strong Commercial Progress and Pipeline Updates for 2025

11 months ago talkbio0Tagged 2025, Attruby, BridgeBio Pharma, Clinical Trials, commercial, FORTIFY, Hereditary Diseases, milestones, Phase 3, Propel, status - In progress

BridgeBio Pharma, Attruby, commercial progress, pipeline updates, 2025 milestones, rare genetic diseases, Phase 3 clinical trials, FORTIFY, CALIBRATE, PROPEL 3.

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion to Strengthen Neuroscience Portfolio

11 months ago talkbio0Tagged Acquisition, Biological Factors, Caplyta, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Biopharmaceutical

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio

11 months ago talkbio0Tagged Acquisition, Caplyta, Depression, Bipolar, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline, Schizophrenia

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Bipolar Depression, Schizophrenia, Major Depressive Disorder

AbbVie and Simcere Zaiming Collaborate on Novel Trispecific Antibody for Multiple Myeloma Treatment

11 months ago talkbio0Tagged AbbVie, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CD3 Antigens, GPRC5D, GPRC5D gene, Multiple Myeloma, Simcere, T-Lymphocyte, Trispecific Antibody, Zaiming

AbbVie, Simcere Zaiming, multiple myeloma, trispecific antibody, SIM0500, T-cell engager, GPRC5D, BCMA, CD3

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio

11 months ago talkbio0Tagged Acquisition, Biopharma, Caplyta, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, M&A, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Lumateperone, CAPLYTA, Biopharma, M&A

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio

11 months ago talkbio0Tagged Acquisition, Caplyta, Depression, Bipolar, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline, Schizophrenia

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Caplyta, Lumateperone, Schizophrenia, Bipolar Depression, Major Depressive Disorder

Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

11 months ago talkbio0Tagged BCG Vaccine, BCG-Naïve, Combined Modality Therapy, Event-Free Survival, Inhibitor, Invasive, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, PDCD1 gene, Pfizer, Sasanlimab, subcutaneous

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG